News

Linda Cendales, MD; Mitchell Cox, MD; Gayathri Devi, PhD; Guido Ferrari, MD; Michael Lidsky, MD; Chandler Long, MD; Kevin Southerland, MD; Julie Thacker, MD; Brent Theiling, MD

See recent faculty honors.

When the SARS-CoV-2 virus began a global pandemic, lives changed and were left in uncertainty. How can people combat a novel virus? Vaccines provide an answer.

Dr. Gayathri Devi, Associate Professor in Surgery, Division of Surgical Sciences, was recently appointed to the editorial board for the journal Cancers.

In the wake of a pandemic, the one question that many people have is how to protect themselves from something they cannot physically see. The solution to it is simple to understand, yet complex in its creation­—vaccines. Dr. Guido Ferrari, associate professor of surgery, Dr. David Montefiori, professor of surgery, and Dr.

The Duke Department of Surgery now ranks third among surgery departments nationwide in National Institutes of Health (NIH) funding received in 2019 according to the newly released Blue Ridge rankings. Duke Surgery has continued to rank in the top five nationally over the past 30 years, demonstrating the department’s long-standing commitment to investigate the impact of disease on patient health. With a diverse portfolio, including 78.7% of funding from the NIH, Duke Surgery faculty and staff perform a wide variety of research to improve the human condition.

Zachary Hartman, PhD, Assistant Professor of Surgery, Division of Surgical Sciences, has received an R01 award from the National Institutes of Health (NIH) for his proposal "Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers."

Georgia Beasley, MD, MHS, Assistant Professor of Surgery in the Division of Surgical Oncology, has received a 2019 award from the Duke Cancer Institute (DCI) for her pilot research project, “Oncolytic Poliovirus in Melanoma.” Using an oncolytic poliovirus has already been tested at Duke as a treatment for recurrent glioblastoma, and in Dr. Beasley’s current research, the therapy will be used for treatment refractory melanoma, or melanoma that has not responded to other treatments. 

The Duke Transplant Center (DTC) of the Duke University School of Medicine aims to promote cross-disciplinary clinical, translational, and basic research with the ultimate goal of optimizing transplant organ longevity and improving quality of life of transplant recipients. This is the inaugural annual call from the DTC for proposals for pilot and feasibility studies.